Results 1 to 10 of about 15,553 (191)

The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases

Antibiotics, 2021
Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and Pseudomonas are increasingly reported worldwide and are usually associated with high mortality rates (>30%).
Alberto Enrico Maraolo, Stefano Di Bella, Francesco Luzzaro   +2 more
exaly   +3 more sources

Antimicrobial Resistance Profiles of Pseudomonas aeruginosa in a Korean Community Hospital: In Vitro Activity of Ceftazidime-Avibactam and Other Agents [PDF]

Polish Journal of Microbiology
The novel antibiotic ceftazidime-avibactam was introduced in Korea in 2023. This study evaluated the in vitro susceptibility of Pseudomonas aeruginosa isolates from a community-based hospital to various antibiotics, including ceftazidime-avibactam.
Lee Hyo-Jin, Cho Sung-Yeon, Lee Dong-Gun, Park Chulmin, Byun Jihyun, Chun Hye-Sun, Kim Yang Ree   +6 more
doaj   +2 more sources

Ceftazidime-avibactam [PDF]

Revista Española de Quimioterapia, 2021
Ceftazidime is a 3rd generation cephalosporin active against Pseudomonas aeruginosa. Avibactam is an inhibitor of class A, C and some class D β-lactamases. The antibacterial spectrum of ceftazidime-avibactam covers 95% of P. aeruginosa isolates and >99% of enterobacteria, including strains carrying extended-spectrum β-lactamases (ESBLs).
Matesanz, Mayra, Mensa, José
openaire   +2 more sources

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae

Frontiers in Microbiology, 2021
Ceftazidime/avibactam is an important treatment option for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp), however, resistance can emerge during treatment.
Yanqin Huang, Tiffany Wu, Omar Perez, Amisha P. Rana, Liang Chen, Liang Chen, Barry N. Kreiswirth, Michael J. Satlin, Zackery P. Bulman   +8 more
doaj   +1 more source

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates

Antibiotics, 2021
β-lactam–avibactam combinations have been proposed as carbapenem-sparing therapies, but little data exist on their in vitro activities in infections with high bacterial inocula.
Moonsuk Bae, Taeeun Kim, Joung Ha Park, Seongman Bae, Heungsup Sung, Mi-Na Kim, Jiwon Jung, Min Jae Kim, Sung-Han Kim, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Yong Pil Chong   +12 more
doaj   +1 more source

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

Frontiers in Pharmacology, 2021
Background: There is renewed interest in repurposing β-lactam antibiotics for treatment of tuberculosis (TB). We investigated efficacy of cefdinir, that withstand the β-lactamase enzyme present in many bacteria, against drug-susceptible and multi-drug ...
Shashikant Srivastava, Shashikant Srivastava, Tania Thomas, Dave Howe, Lesibana Malinga, Prithvi Raj, Jan-Willem Alffenaar, Jan-Willem Alffenaar, Jan-Willem Alffenaar, Tawanda Gumbo, Tawanda Gumbo   +10 more
doaj   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

Antibiotics, 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann   +7 more
doaj   +1 more source

Increased gene expression and copy number of mutated bla KPC lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae

BMC Microbiology, 2021
Background Resistance to ceftazidime-avibactam was reported, and it is important to investigate the mechanisms of ceftazidime/avibactam resistance in K. pneumoniae with mutations in bla KPC. Results We report the mutated bla KPC is not the only mechanism
Lingxiao Sun, Haibo Li, Qi Wang, Yingmei Liu, Bin Cao   +4 more
doaj   +1 more source

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates

Antibiotics, 2021
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montaña, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso, Maria Soledad Ramirez   +13 more
doaj   +1 more source

Cefiderocol Resistance in Klebsiella pneumoniae Is Linked to SHV Extended-Spectrum β-Lactamase Activities and Functional Loss of the Outer Membrane Porin OmpK35

Microbiology Spectrum, 2023
Klebsiella pneumoniae AR 0047 from the CDC and FDA Antibiotic Resistance Isolate Bank is resistant to cefiderocol, a siderophore-conjugated cephalosporin.
Sun Hee Moon, En Huang
doaj   +1 more source